Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Public Citizen's FDA? Lurie Is Consumer Group's Third In Key Agency Role

Executive Summary

FDA's appointment of a high-profile consumer advocate to an Office of the Commissioner post continues a strategy of bringing some of the most outspoken critics of both the drug industry and its regulatory agency into FDA

You may also be interested in...



Lilly Outside "Faculty" Is Headed By 22 Physicians Receiving $50,000 Or More

The most highly paid Lilly outside physician consultant in the first quarter of 2009 - San Jose, Calif., psychiatrist Manoj Waikar ($70,050) - says he was convinced that the public listing of financial ties was a good idea when his patients said they approved of his work with pharmaceutical companies

Public Citizen Seeks To Hold Up Lilly Prasugrel Review For Further Data

Public Citizen's decision to file a citizen petition June 3 asking FDA to halt its review of Lilly/Daiichi Sankyo's prasugrel suggests the watchdog group may believe the agency is on the verge of approving the platelet inhibitor

Collaring Wolfe: Propoxyphene Moves Activist Back To Public Supplicant Role

For almost four decades, one of the most painful public relations challenges for drug companies has been the need to respond quickly to surprise petitions from Public Citizen's Health Research Group asking FDA to withdraw a drug for an alleged safety issue

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051616

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel